March 2026 - Page 7 of 27

WednesdayMar 25, 2026 9:10 am

QualityStocksNewsBreaks – VolitionRx Limited (NYSE American: VNRX) Reports Over 95% Early-Stage Cancer Detection Using Capture-Seq Technology

VolitionRx (NYSE American: VNRX) announced proof-of-concept data from a blinded validation cohort demonstrating over 95% sensitivity for stage I and II cancers with 95% specificity using its Capture-Seq liquid biopsy technology. The study, which included 81 subjects, showed detection rates of 94% for stage I and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%, highlighting the technology’s potential for early cancer detection. Volition said Capture-Seq is designed to enrich and purify circulating tumor DNA for analysis and may support applications in multi-cancer early detection and minimal residual disease monitoring. The company noted the technology…

WednesdayMar 25, 2026 9:00 am

MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’

The company is developing an institutional Digital Asset Treasury model focused on enabling corporations to manage and generate yield from Bitcoin holdings. Its ecosystem integrates multiple verticals, including AdTech, InsurTech, AI Governance, and ClimateTech, within a unified blockchain-enabled framework. The $NILA token serves as a central mechanism for governance, incentives, and interoperability across the platform. The company operates across several large and expanding markets, including decentralized finance, digital advertising, artificial intelligence, and sustainability-focused finance. Its structure as a publicly traded entity combined with a decentralized ecosystem positions it to pursue both institutional adoption and broader ecosystem participation. MindWave Innovations (NYSE…

TuesdayMar 24, 2026 11:40 am

QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Closes $4M Registered Direct Offering Led By Aegis

ParaZero Technologies (NASDAQ: PRZO) announced the closing of its previously announced registered direct offering with a single institutional investor, generating approximately $4 million in gross proceeds through the sale of 5,333,333 ordinary shares and pre-funded warrants at $0.75 per share. The transaction, which closed March 24, 2026, will support general corporate purposes and working capital, with Aegis Capital Corp. acting as exclusive placement agent. To view the full press release, visit https://ibn.fm/tNvse About ParaZero Technologies ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry. Founded in 2014 by aviation professionals and drone industry veterans, ParaZero is a…

TuesdayMar 24, 2026 11:17 am

QualityStocksNewsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Begins Trading On Frankfurt Stock Exchange

Rail Vision (NASDAQ: RVSN) announced that its ordinary shares have begun trading on the Frankfurt Stock Exchange under the symbol C80, while continuing to trade on the Nasdaq Capital Market under RVSN. The company said the dual listing is expected to enhance visibility and trading liquidity in Europe, broaden its investor base and provide expanded access to European institutional and retail investors. To view the full press release, visit https://ibn.fm/g82bl About Rail Vision Ltd. Rail Vision is a development stage technology company that is seeking to revolutionize railway safety and the data-related market. The company has developed cutting edge, artificial intelligence based, industry-leading technology specifically…

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

TuesdayMar 24, 2026 11:02 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc

Earth Science Tech (OTC: ETST) announced the official launch of MyOnlineConsultation.com through MOCTeledoc LLC, a fully integrated doctor network providing technology and clinical staffing solutions to digital health companies, following a beta phase that achieved cash-flow-positive status. The platform supports ETST’s vertically integrated healthcare ecosystem by connecting its prescriber network with compounding pharmacies, including RxCompound and Mister Meds, while offering turnkey telehealth technology, clinical staffing and integrated fulfillment as the company positions MOCTeledoc as a new revenue stream alongside divisions that generated $25.9 million for the nine months ended Dec. 31, 2025. To view the full press release, visit https://ibn.fm/0X6W1 About Earth Science Tech, Inc. (ETST) Earth Science…

TuesdayMar 24, 2026 10:55 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026. To view the full press release, visit https://ibn.fm/Qgb32…

TuesdayMar 24, 2026 10:30 am

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Sees Important Geological Indicators for Advancing Clayton Silver Project Exploration

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, sees compelling prospects for unexplored areas of the project, magnified by the growing value of silver According to J.P. Morgan Global Research, silver prices are projected to average $81/oz in 2026, double their average in 2025, encouraging aggressive exploration of the historically productive but largely unexplored site In January 2026, the company commenced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000…

TuesdayMar 24, 2026 10:17 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Participation In Global Energy And Hydrogen Research Events

American Fusion (OTC: AMFN) is participating in key industry events, including the 17th International Workshop on Anomalies in Hydrogen Loaded Metals (IWAHLM-17), held March 24-26, 2026 in Bergamo, Italy, and the Applied Power Electronics Conference (APEC), taking place March 22-26, 2026 in San Antonio, Texas. The engagements bring together researchers, engineers and industry participants focused on hydrogen-metal systems, power electronics and advanced energy technologies, and are part of the company’s ongoing efforts to remain involved in technical discussions, monitor developments across related fields and build relationships within the broader energy and infrastructure ecosystem. To view the full press release, visit https://ibn.fm/67rUb About American Fusion Inc. American Fusion Inc. (OTC: AMFN) is an…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

Site Search

Company Search

Month: March 2026